Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GBMA Welcomes Australian Budget Co-Payment Commitment

Government Has Committed To Cutting AUD12.50 From PBS Co-Payment

Executive Summary

The Australian government has committed to cutting co-payments for medicines listed on its pharmaceutical benefits scheme by 30%, a move which has been praised by the country’s Generic and Biosimilar Medicines Association.

You may also be interested in...



Australian Industry Gets Price Rises To Offset Cost Of New Anti-Shortage Rules

Australia’s health department has issued guidance giving more details of the requirement to hold minimum levels of stocks of specified medicines from mid-2023.

Australian Industry Working To Minimize Medicines Shortages

Australia’s branded and generic drug industry associations have jointly raised concerns about the impact ongoing shortages could have on the country’s supply of medicines.

Australia’s GBMA Emphasizes Biosimilars Amid Government Change

As Australia’s GBMA launches its latest Biosimilars Awareness Week – the last under a five-year education grant – the association says it is looking forward to “the dawn of a new era” as it begins working with the newly-elected Labor government.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152250

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel